First Publications and Research
In collaboration with AIMST University, we are advancing research in TRIB2 gene knockdown for AML (Acute Myeloid Leukemia) and hematopoietic stem cell expansion to address future blood shortages.
Background: Acute Myeloid Leukemia (AML) is a complex, genetically driven cancer disease with several mutations that complicate therapy regimes. The Tribbles gene family, specifically the TRIB2 gene, has garnered substantial interest as a crucial oncogenic factor of AML progression. Studying cancer through gene expression studies and focusing on the primary oncogenes provide accurate information for future therapies. Here, CRISPR stands as the most exceptional tool used to explore both oncogene functionalities and therapeutic utilities. The ribonucleoprotein (RNP) mode of CRISPR formation and usage are preferred compared to plasmid-mediated CRISPR systems, however, it can lead to complications post-transfection to sensitive cellular entities such as human cancer cells in-vitro, transcribing to similar outcomes in-vivo as well. Therefore, this study describes the use of in-house designed CRISPR-RNP systems targeting the TRIB2 oncogene and evaluates their post-transfection cellular safety and efficacy aspects for future clinical applications.
Find out more details at:
Second Publications and Research
Note: Patent filings for related technologies and methods are currently in progress.
Ex vivo expanded autologous hematopoietic stem cells stimulate improved immunogenic activity: an in-vitro preliminary study for future clinical uses (July 2026)
Background: Hematopoietic stem cell therapy is a cornerstone of regenerative medicine for treating haematological and immunological disorders. While autologous HSCs avoid the complications of graft-versus-host disease, current expansion protocols often rely on expensive synthetic media and xeno-derived components that hinder clinical translation. This study evaluates a minimalist, "in-house" expansion protocol designed for cost-effectiveness and complete human and Malaysian cGMP process compatibility.
Find out more details at: